Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BelaMaf-Kd for relapsed/refractory multiple myeloma
ACTRN12620000490976Phase 2Recruiting
- Sponsor
- Australasian Myeloma Research Consortium
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of belantamab mafodotin, carfilzomib and dexamethasone in multiple myeloma (MM) (2 cohorts), sponsored by Australasian Myeloma Research Consortium. Primary endpoint: Preliminary efficacy of BelaMaf-Kd combination therapy. Started Jan 2021; status: recruiting.
02
Drugs
belantamab mafodotincarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12620000490976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000490976.